Latest News | Granules Gets USFDA Nod for Generic Gout Medication
Get latest articles and stories on Latest News at LatestLY. Drug firm Granules India on Tuesday said it has received approval from the US health regulator to market a medication used to prevent or treat gout attacks.
New Delhi, Apr 30 (PTI) Drug firm Granules India on Tuesday said it has received approval from the US health regulator to market a medication used to prevent or treat gout attacks.
Granules Pharmaceuticals, Inc, a wholly-owned foreign subsidiary of the company, has received approval from the US Food & Drug Administration (USFDA) for Colchicine Capsules (0.6 mg), it said in a regulatory filing.
The company's product is therapeutically equivalent to Hikma International Pharmaceuticals LLC's Mitigare Capsules (0.6 mg), it added.
Colchicine Capsules are indicated for prophylaxis of gout flares in adults.
Also Read | When Is Maharashtra Day 2024? Know About Maharashtra Din Date, History, Celebrations and Significance.
According to industry sources, the current annual market for Colchicine Capsules in the US is expected to be around USD 55 million.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)